Dietmar Berger - 10 Jun 2026 Form 4 Insider Report for GILEAD SCIENCES, INC. (GILD)

Reporting relationship: Chief Medical Officer
Issuer ticker: GILD
Reported as of: 10 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jun 2026, 18:35:57 UTC
Prior SEC filing: 12 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Amy Kim by Power of Attorney for Dietmar Berger

Key filing fact

Dietmar Berger filed Form 4 for GILEAD SCIENCES, INC. (GILD) on 11 Jun 2026.

Key facts

This page summarizes Dietmar Berger's Form 4 filing for GILEAD SCIENCES, INC. (GILD).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 Jun 2026, 18:35.

Change

Previous filing in this sequence was filed on 12 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001739515 Primary reporting owner

Berger Dietmar

Relationship: Chief Medical Officer
Address: 333 LAKESIDE DR., FOSTER CITY
Signature: /s/ Amy Kim by Power of Attorney for Dietmar Berger
Signature date: 11 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GILD transaction

Common Stock

Options Exercise

Transaction value
Shares: +533
Change %: +2.8%
Price
Shares after: 19,515
Date: 10 Jun 2026
Ownership: Direct
Footnotes: F1

GILD transaction

Common Stock

Tax liability

Transaction value
Shares: -263
Change %: -1.3%
Price: $121.48^*
Shares after: 19,252
Date: 10 Jun 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GILD transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
Shares: -533
Change %: -1.1%
Price
Shares after: 46,928
Date: 10 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 533
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Footnote F2

The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.